DHR vs GS: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
VS
The Goldman Sachs Group, Inc. · Financial Services
$1,045.91
-45.0% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
GS trades at a lower forward P/E
(23.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
GS |
| Current Price |
$195.98 |
$1,045.91 |
| Fair Value Estimate |
$211.54 |
$575.25 |
| Upside to Fair Value |
+7.9%
|
-45.0%
|
| Market Cap |
$138.7B |
$308.6B |
| Forward P/E |
37.8x
|
23.6x
|
| EV / EBITDA |
22.8x
|
15.9x
|
| Price / Sales |
5.6x
|
3.1x
|
| Price / FCF |
26.2x
|
-7.4x
|
| Revenue Growth YoY |
+3.7%
|
-35.0%
|
| Gross Margin |
60.7%
|
47.4%
|
| Operating Margin |
21.0%
|
17.8%
|
| Return on Equity |
7.1%
|
15.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.81%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. Despite its strong brand and competitive position in financial capital markets, the company currently faces significant headwinds as evidenced by a 35% decline in revenue and a 100% drop in earnings in the most recent quart…
Accumulation Zones
| Metric |
DHR |
GS |
| Zone Low |
$158.66 |
$431.44 |
| Zone High |
$179.81 |
$488.96 |
| In Buy Zone? |
No
|
No
|